COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium

Kirsten M. Williams; P. T. Wilson; F. Silva-Palacios; J. Kebbe; A. D. LaBeaud; Higuita Agudelo; R. F. Sidonio; S. R. Stowell; C. D. Josephson; B. A. Tarini; J. L. Holter Chakrabarty; A. L. Agwu

doi:10.1016/j.jtct.2021.02.036

COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium

Kirsten M. Williams, P. T. Wilson, F. Silva-Palacios, J. Kebbe, A. D. LaBeaud, Higuita Agudelo, R. F. Sidonio, S. R. Stowell, C. D. Josephson, B. A. Tarini, J. L. Holter Chakrabarty, A. L. Agwu

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

As we pass the nearly 9 month mark of the coronavirus virus disease 2019 (COVID-19) pandemic in the United States, we sought to compile a brief multi-disciplinary compendium of COVID-19 information learned to date. COVID-19 is an active viral pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that confers high morbidity and mortality. COVID-19 has been associated with: pulmonary compromise and acute respiratory distress syndrome, thrombotic events, inflammation and cytokine, and post-infectious syndromes. Mitigation of these complications and expeditious therapy are a global urgency; this is brief summary of current data and management approaches synthesized from publications, experience, cross-disciplinary expertise (Figure 1).

Original language	English (US)
Pages (from-to)	474.e1-474.e3
Journal	Transplantation and Cellular Therapy
Volume	27
Issue number	6
DOIs	https://doi.org/10.1016/j.jtct.2021.02.036
State	Published - Jun 2021

Keywords

COVID-19
compendium
treatment guidance

ASJC Scopus subject areas

Hematology
Transplantation
Immunology and Allergy
Cell Biology
Molecular Medicine
General Medicine

Access to Document

10.1016/j.jtct.2021.02.036

Cite this

Williams, K. M., Wilson, P. T., Silva-Palacios, F., Kebbe, J., LaBeaud, A. D., Agudelo, H., Sidonio, R. F., Stowell, S. R., Josephson, C. D., Tarini, B. A., Holter Chakrabarty, J. L., & Agwu, A. L. (2021). COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium. Transplantation and Cellular Therapy, 27(6), 474.e1-474.e3. https://doi.org/10.1016/j.jtct.2021.02.036

@article{c2acd712055244d0a05f113daaff2915,

title = "COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium",

abstract = "As we pass the nearly 9 month mark of the coronavirus virus disease 2019 (COVID-19) pandemic in the United States, we sought to compile a brief multi-disciplinary compendium of COVID-19 information learned to date. COVID-19 is an active viral pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that confers high morbidity and mortality. COVID-19 has been associated with: pulmonary compromise and acute respiratory distress syndrome, thrombotic events, inflammation and cytokine, and post-infectious syndromes. Mitigation of these complications and expeditious therapy are a global urgency; this is brief summary of current data and management approaches synthesized from publications, experience, cross-disciplinary expertise (Figure 1).",

keywords = "COVID-19, compendium, treatment guidance",

author = "Williams, {Kirsten M.} and Wilson, {P. T.} and F. Silva-Palacios and J. Kebbe and LaBeaud, {A. D.} and Higuita Agudelo and Sidonio, {R. F.} and Stowell, {S. R.} and Josephson, {C. D.} and Tarini, {B. A.} and {Holter Chakrabarty}, {J. L.} and Agwu, {A. L.}",

note = "Funding Information: Conflict of interest statement: All authors have no relevant conflict of interest for this work. A.L.A. has served as an HIV expert on the scientific advisory board of Gilead Sciences and on an expert advisory panel and as a consultant for Merck Pharmaceuticals for HIV therapies. Searches for institutional funding from Gilead (remdesivir) and Roche (Tociluzumab) revealed only that Emory University received a COMPASS grant from Gilead for HIV therapies. No known monetary compensation from industry related to COVID-19 is forthcoming to the hospitals/authors listed herein. Publisher Copyright: {\textcopyright} 2021 The American Society for Transplantation and Cellular Therapy",

year = "2021",

month = jun,

doi = "10.1016/j.jtct.2021.02.036",

language = "English (US)",

volume = "27",

pages = "474.e1--474.e3",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - COVID-19 Cliff Notes

T2 - A COVID-19 Multidisciplinary Care Compendium

AU - Williams, Kirsten M.

AU - Wilson, P. T.

AU - Silva-Palacios, F.

AU - Kebbe, J.

AU - LaBeaud, A. D.

AU - Agudelo, Higuita

AU - Sidonio, R. F.

AU - Stowell, S. R.

AU - Josephson, C. D.

AU - Tarini, B. A.

AU - Holter Chakrabarty, J. L.

AU - Agwu, A. L.

N1 - Funding Information: Conflict of interest statement: All authors have no relevant conflict of interest for this work. A.L.A. has served as an HIV expert on the scientific advisory board of Gilead Sciences and on an expert advisory panel and as a consultant for Merck Pharmaceuticals for HIV therapies. Searches for institutional funding from Gilead (remdesivir) and Roche (Tociluzumab) revealed only that Emory University received a COMPASS grant from Gilead for HIV therapies. No known monetary compensation from industry related to COVID-19 is forthcoming to the hospitals/authors listed herein. Publisher Copyright: © 2021 The American Society for Transplantation and Cellular Therapy

PY - 2021/6

Y1 - 2021/6

N2 - As we pass the nearly 9 month mark of the coronavirus virus disease 2019 (COVID-19) pandemic in the United States, we sought to compile a brief multi-disciplinary compendium of COVID-19 information learned to date. COVID-19 is an active viral pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that confers high morbidity and mortality. COVID-19 has been associated with: pulmonary compromise and acute respiratory distress syndrome, thrombotic events, inflammation and cytokine, and post-infectious syndromes. Mitigation of these complications and expeditious therapy are a global urgency; this is brief summary of current data and management approaches synthesized from publications, experience, cross-disciplinary expertise (Figure 1).

AB - As we pass the nearly 9 month mark of the coronavirus virus disease 2019 (COVID-19) pandemic in the United States, we sought to compile a brief multi-disciplinary compendium of COVID-19 information learned to date. COVID-19 is an active viral pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that confers high morbidity and mortality. COVID-19 has been associated with: pulmonary compromise and acute respiratory distress syndrome, thrombotic events, inflammation and cytokine, and post-infectious syndromes. Mitigation of these complications and expeditious therapy are a global urgency; this is brief summary of current data and management approaches synthesized from publications, experience, cross-disciplinary expertise (Figure 1).

KW - COVID-19

KW - compendium

KW - treatment guidance

UR - http://www.scopus.com/inward/record.url?scp=85104297192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104297192&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2021.02.036

DO - 10.1016/j.jtct.2021.02.036

M3 - Article

C2 - 33686384

AN - SCOPUS:85104297192

SN - 2666-6367

VL - 27

SP - 474.e1-474.e3

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 6

ER -

COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this